William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty
uniQure N.V. (NASDAQ:QURE) ranks among the most oversold biotech stocks to invest in. William Blair reaffirmed its Market Perform rating for uniQure N.V.








